Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

BACKGROUND: Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain. Ponatinib (AP24534) is a potent oral tyrosine kinas...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Cortes, Jorge E., Kantarjian, Hagop, Shah, Neil P., Bixby, Dale, Mauro, Michael J., Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I., Rivera, Victor M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Druker, Brian J., Deininger, Michael W.N., Talpaz, Moshe
Format: Artigo
Sprog:Inglês
Udgivet: 2012
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3777383/
https://ncbi.nlm.nih.gov/pubmed/23190221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1205127
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker